Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort study.
Rousseau A, Michiels S, Simon-Tillaux N, Lolivier A, Bonastre J, Planchard D, Barlesi F, Remon J, Lavaud P, Aldea M, Frelaut M, Le Pechoux C, Botticella A, Levy A, Gazzah A, Foulon S, Besse B.
Rousseau A, et al. Among authors: planchard d.
Lancet Reg Health Eur. 2024 Jun 29;43:100970. doi: 10.1016/j.lanepe.2024.100970. eCollection 2024 Aug.
Lancet Reg Health Eur. 2024.
PMID: 39040528
Free PMC article.